Skip to main content
. 2019 Oct 22;10(58):6111–6123. doi: 10.18632/oncotarget.27222

Figure 4. FLT3 downstream signaling analysis.

Figure 4

(A) MOLM-13 cells were treated with gilteritinib or quizartinib in the presence or absence of FL at 25 ng/mL for 2 hours. Cells were lysed and subjected to western blotting analysis using the indicated antibodies. (B) Phospho-ERK1/2 levels were determined using the phospho-ERK assay kit. The experiment was performed in triplicate, and data are shown as mean ± SD. (C) MOLM-13 cells were treated with quizartinib in combination with or without trametinib in the presence or absence of FL at 25 ng/mL for 2 days. Cell viability was measured using the CellTiter-Glo 2.0 Assay. Cell viability was calculated by defining the survival of quizartinib-untreated cells with or without trametinib treatment and medium control wells as 100% and 0%, respectively. Three experiments were performed in triplicate, and data are shown as mean ± SEM. Abbreviation: FL, FLT3 ligand.